Cannabiz editor-at-large Rhys Cohen says improving patient access needs more than clinics and trail-blazing doctors.

It’s been nearly six years since I first got involved in medicinal cannabis policy in Australia. Recently I’ve been trying to take a longer-term view of things, looking back at some of the challenges we’ve experienced and the progress that we’ve made as a community.

I remember the first time we saw the number of monthly SAS-B approvals hit 100, back in 2018. It was a brutal time for patient access, but hitting 100 felt like a real achievement. The next year we broke 1,000. Two years after that we hit 10,000.

Join the Cannabiz revolution

Want to stay ahead of the cannabis curve with the latest local and international news, analysis and intelligence and access to Australia's legal cannabis industry?

This article is included with our Premium subscription.

Vel turpis nunc eget lorem dolor sed. Sit amet consectetur adipiscing elit duis tristique sollicitudin nibh. Nisl nunc mi ipsum faucibus vitae.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

Rhys Cohen

As well as being editor-at-large at Cannabiz, Rhys is the director of Cannabis Consulting Australia, which provides commercial consulting services to various domestic and international cannabis companies....

Join the Conversation

1 Comment

  1. Great article, Rhys. AMCA and SCCAC are fully supportive of independent prescriber education. We will continue to work on supporting and developing such courses, and working with mainstream clinicians and their colleges to improve their acceptance as truly neutral.
    Gail Wiseman, General Manager – AMCA and SCCAC